Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications - Joint Commission Journal on Quality and Patient Safety: New specialty drugs such as biologics are now available in record numbers, presenting
increased safety risks for people with immune-mediated diseases. However, comprehensive
assessments of patient safety for these drugs are lacking. We examined performance
on key patient safety measures, such as screening for latent tuberculosis (LTBI),
hepatitis B virus (HBV), and hepatitis C virus (HCV), for new users of a broad group
of specialty medications.